You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 20, 2024

CLINICAL TRIALS PROFILE FOR ALIMTA


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Alimta

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00022646 ↗ Pemetrexed Disodium Plus Gemcitabine in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Completed National Cancer Institute (NCI) Phase 2 2001-08-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug and giving the drugs in different ways may kill more tumor cells. PURPOSE: Randomized phase II trial to compare the effectiveness of three different regimens of pemetrexed disodium plus gemcitabine in treating patients who have locally advanced or metastatic non-small cell lung cancer.
NCT00022646 ↗ Pemetrexed Disodium Plus Gemcitabine in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Completed Alliance for Clinical Trials in Oncology Phase 2 2001-08-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug and giving the drugs in different ways may kill more tumor cells. PURPOSE: Randomized phase II trial to compare the effectiveness of three different regimens of pemetrexed disodium plus gemcitabine in treating patients who have locally advanced or metastatic non-small cell lung cancer.
NCT00034463 ↗ ALIMTA (Pemetrexed) in Patients With Locally Advanced or Metastatic Cancer Completed Eli Lilly and Company Phase 1 1969-12-31 This is a non-randomized, phase 1, study with the primary objective of determining the toxicities and establishing the maximum tolerated dose of ALIMTA when administered as a 10 minute infusion every 21 days with folic acid or multi-vitamin supplementation therapy in lightly or heavily pre-treated patients with locally advanced or metastatic cancer.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Alimta

Condition Name

Condition Name for Alimta
Intervention Trials
Non-Small Cell Lung Cancer 53
Lung Cancer 34
Non Small Cell Lung Cancer 32
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Alimta
Intervention Trials
Carcinoma, Non-Small-Cell Lung 200
Lung Neoplasms 187
Mesothelioma 24
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Alimta

Trials by Country

Trials by Country for Alimta
Location Trials
China 88
United Kingdom 78
Spain 66
Italy 61
Canada 57
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Alimta
Location Trials
California 70
Florida 65
Pennsylvania 65
Texas 64
Ohio 62
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Alimta

Clinical Trial Phase

Clinical Trial Phase for Alimta
Clinical Trial Phase Trials
Phase 4 6
Phase 3 52
Phase 2/Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Alimta
Clinical Trial Phase Trials
Completed 196
Terminated 54
Recruiting 28
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Alimta

Sponsor Name

Sponsor Name for Alimta
Sponsor Trials
Eli Lilly and Company 145
National Cancer Institute (NCI) 56
Genentech, Inc. 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Alimta
Sponsor Trials
Industry 268
Other 244
NIH 56
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.